為達最佳瀏覽效果,建議使用 Chrome、Firefox 或 Microsoft Edge 的瀏覽器。

請至Edge官網下載 請至FireFox官網下載 請至Google官網下載
晴時多雲

    限制級
    您即將進入之新聞內容 需滿18歲 方可瀏覽。
    根據「電腦網路內容分級處理辦法」修正條文第六條第三款規定,已於網站首頁或各該限制級網頁,依台灣網站分級推廣基金會規定作標示。 台灣網站分級推廣基金會(TICRF)網站:http://www.ticrf.org.tw

    《TAIPEI TIMES》 Moderna vaccine under FDA review

    A vial of the Moderna COVID-19 vaccine is displayed in Oklahoma City, Oklahoma, on Feb. 19.
Photo: AP

    A vial of the Moderna COVID-19 vaccine is displayed in Oklahoma City, Oklahoma, on Feb. 19. Photo: AP

    2021/03/01 03:00

    By Lee I-chia / Staff reporter

    Taiwan is reviewing an emergency use authorization application by Moderna Inc for its COVID-19 vaccine, the Central Epidemic Command Center (CECC) said yesterday.

    The center had secured 5.05 million doses of the Moderna vaccine.

    However, as Moderna does not have a branch in Taiwan, the Centers for Disease Control (CDC) has forwarded the documents provided by the company and applied to the Food and Drug Administration (FDA) for an emergency use authorization, said CDC Deputy Director-General Chuang Jen-hsiang (莊人祥), who is the CECC’s spokesman.

    The application is being reviewed by the FDA, he said.

    Meanwhile, the COVAX global vaccine distribution platform has yet to inform the CECC about when it would deliver the first batch of the AstraZeneca PLC vaccine to Taiwan.

    COVAX was supposed to announce a delivery schedule by late last month.

    Chuang said Taiwan’s representative office in Geneva, Switzerland, made an inquiry on the matter with COVAX, upon the CECC’s request.

    COVAX said it is still dealing with some issues and currently cannot inform each country when it would receive the first batch of vaccines, he said, adding that the delay is not solely targeted at Taiwan.

    Separately yesterday, the CECC reported an imported case of COVID-19 — a Taiwanese student who returned from Poland.

    The student traveled to Poland in September last year, returned to Taiwan on Jan. 28 and was quarantined at a relative’s residence without showing any symptoms, Chuang said.

    The student on Feb. 12 returned to his home to undergo self-health management, he added.

    He underwent a paid polymerase chain reaction (PCR) test at a hospital on Friday, as he was planning to return to Poland for study, and the test result came back positive the same day, with a cycle threshold value of 35, indicating a low viral load, Chuang said.

    The student tested negative in a second PCR test on Saturday, while his antibody tests came back negative for IgM antibodies and positive for IgG antibodies, so he likely contracted the disease a while ago in Poland, he added.

    Taiwan has had 919 confirmed COVID-19 cases, with 27 patients being isolated in hospital for treatment, Chuang said.

    As of Saturday, the COVID-19 incidence rate in Taiwan is four per 100,000 people, while the global incidence rate is 1,473.5 per 100,000 people, said CDC Director-General Chou Jih-haw (周志浩), head of the CECC’s disease surveillance division.

    Taiwan ranked 186th among 193 countries with regard to incidence rates, and most of the countries with lower incidence rates have smaller populations than Taiwan, he said.

    COVID-19 deaths per million in Taiwan is about 0.4, which ranks the nation 179th among 193 countries, he added.

    The infection fatality rate in Taiwan is about 0.9, while the global infection fatality rate is about 2.2, which suggests that Taiwan has taken good care of its COVID-19 patients, Chou said.

    新聞來源:TAIPEI TIMES

    不用抽 不用搶 現在用APP看新聞 保證天天中獎  點我下載APP  按我看活動辦法

    焦點今日熱門

    網友回應

    此網頁已閒置超過5分鐘,請點擊透明黑底或右下角 X 鈕。